4Gabizon AA.Stealth loposomes and tumor targeting:one step further in the quest for the magic bullet.Clin Cancer Res,2001,7:223-225.
5Eliaz RE,Szoka FC Jr.Liposome encapsulated doxorubicin targeted to CD44:a strategy to kill CD44-overexp-ressing tumor cells.Cancer Res,2001,61:2592-2601.
6Moiseyenko VM,Danilov AO,Baldueva IA,et al.Phase Ⅰ/Ⅱ trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors.Ann Onc,2005,16:162-168.
7Qian DZ,Wang XF,Kachhap SK,et al.The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine Kinase Inhibitor PTK787/ZK222584.Cancer Res,2004,64:6626-6634.
8Tommaso DP,Giuseppe P,Filippo B,et al.Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.Clin Oncol,2004,22:4966-4970.
2Beyer DC, Puente F, Rogers KL, et al. Prostate brachy therapy: comparison of dose distribution with different 125Ⅰ source designs[J]. Radiology, 2001, 221 (3) :623.
3Ankem MK, DeCarvalho VS, Harangozo AM, et al. Implications of radioactive seed migration to the lungs after prostate brachytherapy[J]. Urology, 2002,59 (4): 555.
4Raben A, Mychalczak B. Brachy-therapy for non-small cell lung cancer and selected neoplasms of the chest[J]. Chest, 1997,112: 276s.
5Chen A, Galloway M, Landreneau R, et al. Intraopera tive 125Ⅰbrachytherapy for high-risk stage Ⅰ non-small cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2000 ,6(4): 1083.
